Do big R&D budgets justify US premium drug prices? No way, analysts scoff
Do you want a new formula for calculating “excess” prices paid for branded drug prices? A group of healthcare researchers found a ripe prospect: Tackling …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.